Reagents and instruments for immunology, cell biology and molecular biology.

Azithromycin [83905-01-5]

Print

Cat# HY-17506-50mg

Size : 50mg

Contact local distributor :

Phone : +1 850 650 7790

Brand : MedChemExpress

Request more information

Contact local distributor :

Phone : +1 850 650 7790

Azithromycin is a macrolide antibiotic useful for the treatment of a number of bacterial infections.

For research use only. We do not sell to patients.

Azithromycin Chemical Structure

CAS No. : 83905-01-5

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Based on 27 publication(s) in Google Scholar

Other Forms of Azithromycin:

Azithromycin-d₃ Get quote
Azithromycin-¹³C,d₃ Get quote
Azithromycin-d₅ Get quote
Azithromycin hydrate Get quote
Azithromycin (Standard) Get quote

Description

Azithromycin is a macrolide antibiotic useful for the treatment of a number of bacterial infections.

IC₅₀ & Target

Macrolide

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	> 600 μM Compound: Azithromycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 32871342]
HeLa	IC₅₀	160 μg/mL Compound: Azithromycin	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	240 μg/mL Compound: Azithromycin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HepG2	IC₅₀	> 50 μM Compound: 6	Cytotoxicity against human HepG2 cells after 1 to 4 hrs by MTS assay Cytotoxicity against human HepG2 cells after 1 to 4 hrs by MTS assay	[PMID: 21476508]
HepG2	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay	[PMID: 22148880]
HepG2	IC₅₀	203 μM Compound: AZI	Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay	[PMID: 22380766]
HepG2	IC₅₀	203 μM Compound: AZ	Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay	[PMID: 22321992]
HFF	CC₅₀	174 μM Compound: 3	Cytotoxicity against HFF after 48 hrs by MTS assay Cytotoxicity against HFF after 48 hrs by MTS assay	[PMID: 21428405]
MG-63	IC₅₀	180 μg/mL Compound: Azithromycin	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	190 μg/mL Compound: Azithromycin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	160 μg/mL Compound: Azithromycin	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	25 μg/mL Compound: Azithromycin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]
THP-1	IC₅₀	> 50 μM Compound: 6	Cytotoxicity against human THP1 cells after 1 to 4 hrs by MTS assay Cytotoxicity against human THP1 cells after 1 to 4 hrs by MTS assay	[PMID: 21476508]
THP-1	EC₅₀	0.024 mg/L Compound: Azithromycin	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as decrease of CFU after 24 hrs Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as decrease of CFU after 24 hrs	[PMID: 19564365]
THP-1	EC₅₀	2.86 mg/L Compound: Azithromycin	Antibacterial activity against methicillin-sensitive Listeria monocytogenes EGD infected in human THP1 cells assessed as decrease of CFU after 24 hrs Antibacterial activity against methicillin-sensitive Listeria monocytogenes EGD infected in human THP1 cells assessed as decrease of CFU after 24 hrs	[PMID: 19564365]
Vero	CC₅₀	> 130 μM Compound: Azithromycin	Cytotoxicity against African green monkey Vero cells by MTT assay Cytotoxicity against African green monkey Vero cells by MTT assay	[PMID: 32871342]
Vero	CC₅₀	> 40 μM Compound: Azithromycin	Cytotoxicity against African green monkey Vero cells by Celltiter blue assay Cytotoxicity against African green monkey Vero cells by Celltiter blue assay	[PMID: 32871342]
Vero	CC₅₀	810 μM Compound: Azithromycin	Antiproliferative against African green monkey Vero cells incubated for 40 hrs by Celltiter assay Antiproliferative against African green monkey Vero cells incubated for 40 hrs by Celltiter assay	[PMID: 32871342]
Vero C1008	CC₅₀	> 40 μM Compound: Azithromycin	Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm) Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm)	10.1101/2020.04.03.023846
Vero C1008	EC₅₀	2.12 μM Compound: Azithromycin	Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days	10.1101/2020.04.03.023846

In Vitro

Azithromycin (2 μM) augments rhinovirus-induced IFNβ expression in primary bronchial epithelial cells from asthmatics, which is associated with over-expression of RIG-I like receptors and repression of viral replication. Knockdown of MDA5, but not knockdown of RIG-I, diminishes azithromycin (2 μM)-enhanced viral-induced IFNβ expression in asthmatic primary bronchial epithelial cells^[1]. Azithromycin specifically reduces MMP-9 mRNA and protein levels without affecting NF-κB in endotoxin-challenged monocytic THP-1 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (133.51 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.3351 mL	6.6757 mL	13.3515 mL
5 mM	0.2670 mL	1.3351 mL	2.6703 mL
10 mM	0.1335 mL	0.6676 mL	1.3351 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (3.34 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: ≥98.0%

Select Batch:

SDS (393 KB)

COA (257 KB) HNMR (304 KB)

Handling Instructions (2659 KB)

References

[1]. Menzel M, et al. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017 Mar 18. [Content Brief]

[2]. Vandooren J, et al. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS One. 2017 Apr 3;12(4):e0174853. [Content Brief]

Cell Assay ^[2]	THP-1 cells (10⁶ cells in 1 mL RPMI medium, without antibiotics, growth factors or serum) are seeded in each well of 24-well plates and allowed to settle for 1 hour. Next, 50 μL of the test compound is added followed by 50 μL of LPS (final concentration of 10 μg/mL). After 24h (37°C and 5% CO₂) the supernatants and cell pellets are collected (1200 rpm, 5 min). THP-1 cell viability is tested using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). MTT is dissolved at 2 mg/mL in PBS and aliquots are stored at -20°C. The MTT assay is performed according to the suppliers instructions. Absorbance of MTT converted into formazan is measured at a wavelength of 570 nm with background subtraction at 630 nm. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Menzel M, et al. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017 Mar 18. [Content Brief] [2]. Vandooren J, et al. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS One. 2017 Apr 3;12(4):e0174853. [Content Brief]

Cell Assay
^[2]

THP-1 cells (10⁶ cells in 1 mL RPMI medium, without antibiotics, growth factors or serum) are seeded in each well of 24-well plates and allowed to settle for 1 hour. Next, 50 μL of the test compound is added followed by 50 μL of LPS (final concentration of 10 μg/mL). After 24h (37°C and 5% CO₂) the supernatants and cell pellets are collected (1200 rpm, 5 min). THP-1 cell viability is tested using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). MTT is dissolved at 2 mg/mL in PBS and aliquots are stored at -20°C. The MTT assay is performed according to the suppliers instructions. Absorbance of MTT converted into formazan is measured at a wavelength of 570 nm with background subtraction at 630 nm.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Menzel M, et al. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017 Mar 18. [Content Brief]

[2]. Vandooren J, et al. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS One. 2017 Apr 3;12(4):e0174853. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.3351 mL	6.6757 mL	13.3515 mL	33.3787 mL
	5 mM	0.2670 mL	1.3351 mL	2.6703 mL	6.6757 mL
	10 mM	0.1335 mL	0.6676 mL	1.3351 mL	3.3379 mL
	15 mM	0.0890 mL	0.4450 mL	0.8901 mL	2.2252 mL
	20 mM	0.0668 mL	0.3338 mL	0.6676 mL	1.6689 mL
	25 mM	0.0534 mL	0.2670 mL	0.5341 mL	1.3351 mL
	30 mM	0.0445 mL	0.2225 mL	0.4450 mL	1.1126 mL
	40 mM	0.0334 mL	0.1669 mL	0.3338 mL	0.8345 mL
	50 mM	0.0267 mL	0.1335 mL	0.2670 mL	0.6676 mL
	60 mM	0.0223 mL	0.1113 mL	0.2225 mL	0.5563 mL
	80 mM	0.0167 mL	0.0834 mL	0.1669 mL	0.4172 mL
	100 mM	0.0134 mL	0.0668 mL	0.1335 mL	0.3338 mL

Azithromycin Related Classifications

Anti-infection Autophagy
Bacterial Autophagy Antibiotic Parasite

Help & FAQs

Keywords:

Azithromycin83905-01-5CP 62993CP62993CP-62993BacterialAutophagyAntibioticParasiteInhibitorinhibitorinhibit

Azithromycin [83905-01-5]

Cat# HY-17506-50mg

Contact local distributor :

Brand : MedChemExpress

Contact local distributor :

Other Forms of Azithromycin:

Azithromycin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Azithromycin Related Classifications

Keywords:

You might also be interested by the following products: